drugset

drugset / Trial / NCT05394675

A Study of DS-9606a in Patients With Advanced Solid Tumors

NCT05394675 ↗

Phase 1 Terminated 88 enrolled Daiichi Sankyo

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.

Timeline

Start: 2022-05-31
Primary completion: 2026-02-06
Completion: 2026-02-06

Outcome

Outcome not reported

Stopped: “It was Daiichi Sankyo, Inc.'s decision to discontinue further internal development of DS-9606a”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DS-9606a	Unknown	0.016 mg/kg	Intravenous

Indications